Sareum Holdings (SAR)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

20.00p
   
  • Change Today:
    -1.00p
  • 52 Week High: 31.00
  • 52 Week Low: 11.25
  • Currency: UK Pounds
  • Shares Issued: 137.22m
  • Volume: 455,276
  • Market Cap: £27.44m
  • RiskGrade: 594

Deal with Barclays    Trade now with Barclays Stockbrokers

Company Listing Data

EPIC SAR
Sector Pharma and Biotech
ISIN GB00BMC3RJ87
Market Sector AIM
Market Segment ASX1
Main Indices FTSE AIM All-Share
Country of register Great Britain
Currency British Pound
Market Cap £27.44m
NMS 2,000
Shares in issue 137.22m
Date Listed 11-Oct-2004

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Sareum Holdings Market Data

Currency UK Pounds
Share Price 20.00p
Change Today -1.00p
% Change -4.76 %
52 Week High 31.00
52 Week Low 11.25
Volume 455,276
Shares Issued 137.22m
Market Cap £27.44m
RiskGrade 594

Sareum Holdings Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
46.86% below the market average46.86% below the market average46.86% below the market average46.86% below the market average46.86% below the market average
2.44% below the sector average2.44% below the sector average2.44% below the sector average2.44% below the sector average2.44% below the sector average
Price Trend
27.48% below the market average27.48% below the market average27.48% below the market average27.48% below the market average27.48% below the market average
9.09% above the sector average9.09% above the sector average9.09% above the sector average9.09% above the sector average9.09% above the sector average
Income Not Available
Growth Not Available

Sareum Holdings Dividends

No dividends found

Trades for 29-Aug-2025

Time Volume / Share Price
16:35 100,000 @ 20.75p
16:36 25,000 @ 20.00p
16:35 40,000 @ 20.00p
16:35 10,000 @ 20.00p
16:35 10,000 @ 20.00p

Sareum Holdings Key Personnel

COO Timothy J Mitchell

Top of Page